Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant

计划入组 40 人 · 首次发布于 2017 年 9 月 29 日

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

计划入组 430 人 · 首次发布于 2022 年 4 月 14 日

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

计划入组 17 人 · 首次发布于 2015 年 6 月 1 日

CMV Specific T Cell donor lymphocyte infusion(Duke University)

Blinatumomab(Blincyto)

Rx

Donor lymphocyte(Celgene Corporation)

NATIONAL MARROW DONOR PROGRAM

United States

BRIOVARX INFUSION SERVICES

United States

ISLA HOME INFUSION, INC

Guam

T Cell Subtype and Bone Marrow Environment Key to DLI Success in AML

Early Detection of Mixed Chimerism Predicts Leukemia Relapse Risk in AML Transplant Patients

Axatilimab Approved for Chronic GVHD After Failure of Two Prior Therapies